Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CholBiome X3
- Development stage
- Unknown
- Lead developer
- OptiBiotix Health
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Small Molecules, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
**CholBiome X3** is an oral cholesterol-lowering nutraceutical developed by **OptiBiotix Health** and marketed as a dietary supplement rather than a prescription medicine. It is a **triple-combination oral tablet** containing the patented probiotic **Lactobacillus plantarum LPLDL**, **monacolin K** derived from red yeast rice, and **vitamin B3**. The product is intended to support cardiovascular health by combining **microbiome-directed cholesterol modulation** with **inhibition of hepatic cholesterol synthesis** and **modulation of lipid metabolism**, with reported goals of lowering total cholesterol and LDL cholesterol, increasing HDL cholesterol, and reducing blood pressure. It is described as a triple-layer tablet formulation containing 4 billion CFU of the probiotic component and has been positioned for management of hypercholesterolemia and broader cardiovascular risk support.
- Brand names
- CholBiome X3CholBiomeX3CholBiomeX-3CholBiomeX 3CholBiome
- Other names
- CholBiome X3 triple-layer tabletCholBiome X3 food supplement
02
Targets
HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)
Beyond the preview
Go deeper on CholBiome X3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CholBiome X3.